The 'burn' of ranitidine recall: current insights and mitigation strategies.

Abstract

Ranitidine was one of the most commonly used medications for the treatment of gastroesophageal reflux disease. On 1 April 2020, the US Food and Drug Administration requested all manufacturers to immediately withdraw ranitidine from the market because of concern of higher than acceptable levels of N-nitrosodimethylamine, a potential carcinogen. Herein, we highlight the reason for this recall, along with the effects of this recall on both the patients and healthcare practitioners, and offer insights on management strategies.

Document Type

Article

Publication Date

4-16-2021

Publication Title

European journal of gastroenterology & hepatology

Link to Full Text

Share

COinS